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Abstract
N-Glycan oxazolines have found widespread use as activated donor substrates for endo-β-N-acetylglucosaminidase (ENGase) en-
zymes, an important application that has correspondingly stimulated interest in their production, both by total synthesis and by
semi-synthesis using oligosaccharides isolated from natural sources. Amongst the many synthetic approaches reported, the majority
rely on the fabrication (either by total synthesis, or semi-synthesis from locust bean gum) of a key Manβ(1–4)GlcNAc disaccharide,
which can then be elaborated at the 3- and 6-positions of the mannose unit using standard glycosylation chemistry. Early ap-
proaches subsequently relied on the Lewis acid catalysed conversion of peracetylated N-glycan oligosaccharides produced in this
manner into their corresponding oxazolines, followed by global deprotection. However, a key breakthrough in the field has been the
development by Shoda of 2-chloro-1,3-dimethylimidazolinium chloride (DMC), and related reagents, which can direct convert an
oligosaccharide with a 2-acetamido sugar at the reducing terminus directly into the corresponding oxazoline in water. Therefore,
oxazoline formation can now be achieved in water as the final step of any synthetic sequence, obviating the need for any further
protecting group manipulations, and simplifying synthetic strategies. As an alternative to total synthesis, significant quantities of
several structurally complicated N-glycans can be isolated from natural sources, such as egg yolks and soy bean flour. Enzymatic
transformations of these materials, in concert with DMC-mediated oxazoline formation as a final step, allow access to a selection of
N-glycan oxazoline structures both in larger quantities and in a more expedient fashion than is achievable by total synthesis.
Review
Introduction
Glycosyl oxazolines are high-energy intermediates on the
hydrolytic pathway of some [1-5] (but not all) [6] of the numer-
ous glycosidases that hydrolyse linkages between 2-acetamido
sugars and other species. In particular the endo-β-N-acetylglu-
cosaminidases [7] (ENGases, EC 3.2.1.96), a class of enzyme
which specifically cleave between the innermost two GlcNAc
residues of N-glycans attached to N-linked glycoproteins, all
operate via a two-step mechanism involving neighbouring
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Scheme 1: The first ENGase-catalysed glycosylation of a GlcNAc acceptor using an N-glycan oxazoline as donor.
Scheme 2: Production of N-glycan oxazolines from peracetylated sugars using Lewis acids.
group participation of the 2-acetamide group and an oxazoline
as a high energy intermediate [8].
Glycosyl oxazolines first drew the attention of synthetic
chemists due to their use as glycosyl donors for the synthesis of
oligosaccharides that comprise 2-amino-2-dexoy sugars [9].
Though the majority of synthetic work focussed on production
and reaction of gluco-configured oxazolines (i.e., those derived
from GlcNAc), the corresponding manno [10,11] and galacto-
configured [12] compounds have also been made and studied.
Although the first generation of these oxazoline donors [13,14]
proved to be rather unreactive, and found only limited applica-
tions [15-18], the addition of three chlorines to the methyl
group did increase their potency [19-23]. However, applica-
tions were still less widespread than more conventional glucos-
amine-derived donors.
Resurgent interest in the production of glycosyl oxazolines, and
in particular oxazoline derivatives of N-glycans, was as a direct
result of their utility as activated donors species for glycosidase-
catalysed synthesis [24-27]. Initially activity centred on the use
of oxazolines as donors for chitinase-catalysed glycosylations
[28-31]. However, a turning point occurred when, in a seminal
publication in 2001 Shoda [32] and co-workers reported that a
disaccharide oxazoline (Scheme 1) was an effective donor sub-
strate for two ENGase enzymes (Endo A and Endo M), both of
which were capable of using it to glycosylate two GlcNAc
acceptors, to produce trisaccharide products.
Subsequently the ENGases in combination with N-glycan oxa-
zolines, have become the biocatalysts of choice for the conver-
gent production of a wide variety of biologically interesting
glycopeptides and for the remodelling of glycoproteins, includ-
ing mAbs [33,34]. The efficient production of N-glycan oxa-
zolines as donor substrates for these enzymes has therefore
become an area of significant interest over the past 15 years
[35,36].
The synthesis of N-glycan oxazolines
Formation of glycosyl oxazolines
Glycosyl oxazolines of monosaccharides can be produced
straightforwardly using strong Lewis acids (e.g., FeCl3, SnCl4,
or TMSOTf) and a fully protected (typically peracetylated)
GlcNAc or other 2-acetamido sugar [37-40]. Oxazoline forma-
tion is achieved by activation of the leaving group at the
anomeric centre and neighbouring group participation by the
2-acetamide. Unfortunately application of these reaction condi-
tions to oligosaccharide substrates leads to significant cleavage
of interglycosidic linkages, and correspondingly low yields of
products. However, two methods that are useful for the produc-
tion of oligosaccharide oxazolines are treatment of the peracety-
lated sugar with either TMSOTf in dichloroethane [39], or with
TMSBr, BF3·Et2O and 2,4,6-collidine in dichloroethane [40]
(Scheme 2). Both procedures give oxazolines of N-glycans in
moderate to good yield with no cleavage of the oligosaccharide
chain; the latter method reportedly gives better yields of more
structurally complex N-glycan oxazolines.
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However, employing protected sugars as substrates presents
some limitations, as any remaining protecting groups must be
removed in a subsequent step. Firstly, and most importantly,
glycosyl oxazolines are extremely labile to acidic hydrolysis,
and so this approach precludes the use of any OH-protecting
groups that require acidic conditions for their cleavage. Second-
ly some glycosyl oxazolines are also prone to reductive
cleavage by catalytic hydrogenation [41], presenting a signifi-
cant further limitation as to which OH-protecting groups may
be employed. Most of the reports in the literature have there-
fore used a protecting group regime in which all of the sugar
hydroxy groups have been protected with base-labile groups,
most commonly acetate esters. Importantly glycosyl oxazolines
are completely stable to the typical basic conditions used for
ester removal (e.g., Zemplen deacetylation). The generally
accepted approach (until 2009) was therefore to perform all
protecting group manipulations/interconversions on the com-
pleted oligosaccharide to ensure that all OH groups were pro-
tected as base-labile esters, before oxazoline formation.
In 2009, Shoda published [42] a paper that was to completely
change the way in which glycosyl oxazolines were made, and
which would ultimately make many more readily available. In
this seminal work, Shoda reported that the treatment of GlcNAc
in aqueous solution with the activating agent 2-chloro-1,3-
dimethylimidazolinium chloride (DMC) in the presence of tri-
ethylamine as the base, led to the formation of the glycosyl oxa-
zoline in good yield (Scheme 3). Moreover this remarkable
transformation was equally applicable to considerably larger
oligosaccharide structures (vide infra). This breakthrough
changed the way that all unprotected N-glycan oxazolines were
to be made from that point in time onwards.
Scheme 3: Direct conversion of unprotected GlcNAc to a glycosyl oxa-
zoline by treatment with DMC and Et3N in water.
Although in later papers Shoda has published alternative
reagents that may be used to achieve the same transformation,
such as 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium chlo-
ride (CDMBI) [43], DMC remains the most popular reagent for
glycosyl oxazoline production. DMC is remarkably tolerant of
other functional groups in the oligosaccharide, for example
sialic acids [44] and phosphates [45,46] are completely unaf-
fected; the former is perhaps rather surprising since DMC was
first developed as a carboxylic acid activating agent for peptide
synthesis by Ishikawa [47]! One caveat to the procedure is that
it is considerably less efficient for GalNAc; in this case the cor-
responding oxazoline is only produced in ≈50% yield. Indeed
some of the other very useful DMC-mediated transformations
of unprotected reducing sugars in aqueous solution that have
been developed recently also work less effectively when the
sugar at the reducing terminus has a galacto configuration
[48-50].
Production of unprotected N-glycan oxazolines by
total synthesis
The majority of the reported syntheses of N-glycan oxazolines
have employed a key selectively protected Manβ(1–4)GlcNAc
disaccharide building block which has then been extended at the
3- and 6-positions of the branching mannose unit. Amongst the
possible ways to synthesise this key disaccharide [51,52] two
have been used predominantly for the synthesis of N-glycan
oxazolines. The OH-2 epimerisation approach, which uses a
gluco-configured donor for glycosylation of the OH-4 of a
selectively protected glucosamine acceptor has been used more
than the other methods. Selective and orthogonal protection of
OH-2 of the donor by an ester group facilitates both the stereo-
selective formation of the desired β-linkage, and also access to
OH-2 after glycosylation for epimerisation. Amongst the many
syntheses [53-58] of N-glycan oxazolines using this approach,
the use of Lev protection on the donor, first developed by
Boons [59], and then triflation and nucleophilic substitution by
acetate aided by sonication, first developed by Fürstner [60,61],
appear to be optimal. An example that employed these key steps
was used to synthesise a truncated complex biantennary
N-glycan oxazoline [62], as shown in Scheme 4. Following the
gluco to manno epimerisation process, selective deprotection of
OH-3 of the mannose unit was followed by glycosylation and
extension of the 3-branched arm. Subsequent removal (or regio-
selective reductive ring-opening) of the 4,6-benzylidene
protecting group allowed a second glycosylation at position 6.
Conversion of all OH-protecting groups to acetate and the
phthalamide to acetamide was followed by oxazoline formation
using TMSBr, BF3·Et2O and 2,4,6-collidine in dichloroethane,
and finally deacetylation. Modifications of this basic strategy
have allowed the synthesis of a wide variety of truncated and
structurally modified glycans [53-59].
Amongst other synthetic approaches that may be used to access
the ‘difficult’ Manβ(1–4)GlcNAc linkage, including a variety of
methods of intramolecular glycosylation [63-71] the most
widely applied has been the Crich direct β-mannosylation
[72-76]. However, one apparent limitation is that generally the
reaction only works well if the GlcNAc acceptor has an azide or
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 4: Total synthesis of a truncated complex biantennary N-glycan oxazoline via an epimerisation approach and Lewis acid mediated oxazoline
formation.
sulfonamide at position 2, rather than acetamide or N-phthal-
amide. Scheme 5 shows an example of the synthesis of a modi-
fied core N-glycan tetrasaccharide oxazoline from the several
reported by Wang [77] using this approach. In this case
following formation of the key Manβ(1–4)GlcNAc disaccha-
ride both the 3- and 6-hydroxy groups of the mannose residue
were deprotected, and the resulting diol underwent a double
glycosylation with a selectively protected trichloroacetimidate
donor.
An added advantaged of approaches that use total synthesis is
the possibility of the incorporation of tags into the glycan struc-
ture, which allows further modifications to be made later. In this
case, following conversion of the azide at position 2 of the
glucosamine unit into an acetamide, azide was introduced at po-
sition 6 of the two terminal mannose residues. Protecting group
interconversions, and peracetylation were followed by conver-
sion to the oxazoline, using TMSBr, BF3·Et2O and collidine,
and finally deacetylation. It was found that the incorporated
azide was tolerated by the ENGase enzyme (Endo A), and so a
modified glycoprotein (RNase) was made by enzymatic attach-
ment of this synthetic tetrasaccharide, to which other species
were then conjugated by click reactions.
In more recent examples conversion of the completely depro-
tected glycan to the oxazoline by treatment with DMC has
become the normal (and most effective) strategy. For example
the same key Manβ(1–4)GlcNAc disaccharide was used by
Wang for the more extended synthesis of a dodecasaccharide
oxazoline (Scheme 6) [78]. In this case selective removal of the
PMB protecting group at OH-3 was followed by glycosylation
with a pentasaccharide glycosyl fluoride donor, comprising one
galactose, one glucose, and three mannose residues. Acid cata-
lysed hydrolysis of the 4,6-benzylidene was followed by regio-
selective glycosylation of the primary 6-OH with a different
pentasaccharide, this time comprised of five mannoses. Conver-
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 5: Wangs’s total synthesis of an N-glycan oxazoline incorporating click handles, employing Crich direct β-mannosylation.
sion of the azide to acetamide and removal of all benzyl groups
by hydrogenolysis produced a completely deprotected dode-
casaccharide, which was finally converted to the glycosyl oxa-
zoline by treatment with DMC in quantitative yield.
Final stage conversion of the fully deprotected oligosaccharide
into the oxazoline has greatly facilitated the synthesis of more
complex N-glycan oxazolines by analogous routes [79,80], in-
cluding those bearing mannose-6-phosphate residues [45,46].
For example as shown in Scheme 7 sequential glycosylation of
the key Manβ(1–4)GlcNAc disaccharide at positions 3 and 6,
using the same selectively protected manno thioglycoside donor
gave a tetrasaccharide. Removal of the silyl protecting groups
revealed the 6-hydroxy groups of the terminal mannose
residues, which were then phosphorylated. Removal of the
anomeric PMP protection was followed by global deprotection
by Birch reduction to give the completely deprotected tetrasac-
charide diphosphate. Finally treatment with DMC in water in
the presence of Et3N resulted in conversion to the glycosyl oxa-
zoline in an excellent 95% yield.
Semi-synthesis: the locust bean gum approach
The naturally occurring polysaccharide locust bean gum
contains a repeating Manβ(1–4)Man disaccharide unit, which is
also decorated with branching α-galactose residues attached to
OH-6 of some of the mannoses. Nishimura and co-workers [81]
realised the potential utility of this Manβ(1–4)Man disaccha-
ride in an expedient route to the part of N-glycans that is most
difficult to synthesise; namely the Manβ(1–4)GlcNAc linkage.
Treatment of locust bean gum with pectinase from Aspergillus
aculeatus, which has both mannosidase and galactosidase activ-
ity, at 50 °C for 48 h in a 50 mM acetate buffer (pH 5.0)
resulted in the production of a mixture of compounds, from
which the Manβ(1–4)Man disaccharide was readily purified by
acetylation (typically in ≈30% overall yield, Scheme 8). In the
key transformation, the mannose residue at the reducing
terminus was then converted into a glucosamine derivative (in
fact possessing an azide at C2) first by conversion to the
glycal and then an azido nitration reaction. This innovative
method is considerably shorter than other approaches to the
Manβ(1–4)GlcNAc (or equivalent) disaccharide. Elegant
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 6: Wangs’s total synthesis of an N-glycan dodecasaccharide oxazoline employing final step oxazoline formation with DMC.
protecting group manipulations, involving the formation of a
dibenzylidene derivative on the mannose ring, benzylation of
the remaining free hydroxy groups on the glucosamine ring, and
then regio- and chemoselective reductive ring opening of the
less stable 5-ring benzylidene with DIBAL, led to a key disac-
charide intermediate in which OH-3 of the mannose unit was
unprotected and in which the 4- and 6-positions were protected
as a benzylidene. Extension of this core disaccharide should be
straightforward by traditional synthetic methodology, and so in
principle the locust bean gum approach should allow rapid
access to a wide variety of more extended N-glycan structures.
In their original publication Nishimura and co-workers first
glycosylated the free OH at position 3 with 2,4-branched trisac-
charide trichloroacetimidate donor 2, removed the 4,6-benzyl-
idene, and then regioselectively glycosylated the free primary
OH at position 6 with 2,6-branched trisaccharide trichloroacet-
imidate donor 3. Following conversion of the Troc groups into
acetamides and reduction and acetylation of the azide, all of the
acetates were removed. Treatment with UDP-Gal and a β(1–4)-
galactosyl transferase led to the addition of galactose residues to
all of the 4-hydroxy groups of the GlcNAcs. Deprotection of the
remaining benzyl protecting groups and removal of the SPh at
the reducing terminus by catalytic hydrogenation gave the
completely deprotected dodecasaccharide. Finally conversion to
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 7: Production of a phosphorylated N-glycan oxazoline, employing final step oxazoline formation with DMC.
the corresponding oxazoline by the use of DMC gave the
tetraantennary complex N-glycan oxazoline in 96% yield
(Scheme 8).
Production of N-glycan oxazolines using
oligosaccharides isolated from natural
sources
The egg yolk approach
The yolk of hens’ eggs contains a glycopeptide, often termed
sialylglycopeptide (SGP), which is comprised of a short peptide
linked to a complex biantennary N-glycan. Thus egg yolks can
serve as a source of this complex biantennary N-glycan
[(NeuAcGalGlcNAcMan)2ManGlcNAc2], following isolation
of SGP, and subsequent enzymatic degradation. The original
procedure [82] for the isolation of SGP first involved depro-
teinization by treatment with 90% phenol and washing with
Et2O, and then repeated purification by size exclusion chroma-
tography (SEC, Sephadex G-50, followed by Sephadex G-25)
from which sialic acid positive fractions were collected. Further
purification by anion exchange chromatography (Sephadex
DEAE eluting with NaCl) removed any non-sialylated glycans,
and was followed by cation exchange chromatography
(Sephadex C-25). Finally desalination using SEC (Sephadex
G-25) gave pure SGP.
Several improvements have subsequently been published which
have made the isolation process easier and improved the yield.
Firstly a significantly shortened procedure [83] followed the
phenol treatment with a single purification by SEC (Sephadex
G-50), and then filtration through graphitized carbon cartridges.
Subsequently an even better method was developed [84] which
avoided the treatment with phenol and all SEC purification
steps (Scheme 9). In this process the egg yolks were first stirred
with water and then freeze dried to give egg yolk powder. This
powder was washed successively with diethyl ether and then
70% aqueous acetone. The solid was then extracted by vigorous
mixing with 40% aqueous acetone. Following filtration through
Celite®, the filtrate was concentrated and freeze-dried. The
powder was dissolved in water and then purified on an active
carbon/Celite® (2:1) column, eluting with 25% MeCN, to give
pure SGP on a gram scale; typically 1.5–2.0 g of SGP is ob-
tained from 300 eggs.
Very recently Boons and co-workers [85] published further
modifications and optimisation of this procedure, and reported
that it is possible to start with commercially produced
lyophilised egg yolk powder, rather than the eggs themselves.
Their method, which also included purification by the use of
preparative hydrophilic interaction chromatography–high per-
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 8: Enzymatic degradation of locust bean gum, and chemical conversion into an N-glycan dodecasaccharide oxazoline.
formance liquid chromatography (HILIC–HPLC), clearly
reduces time and effort by removing the need for separation of
the yolks and freeze-drying. However, care has to be exercised
with respect to the processing that the commercially sourced
egg yolk powder has undergone; for example spray drying
at >100 °C may lead to degradation of the glycans.
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 9: Production of a complex biantennary N-glycan oxazoline from hens’ eggs by semi-synthesis via isolation of SGP, enzymatic degradation,
and final stage oxazoline formation.
Whichever method of SGP production is used, the free oligo-
saccharide [(NeuAcGalGlcNAcMan)2ManGlcNAc] can then be
released from SGP by treatment with the ENGase Endo M [86].
Following purification by SEC (Sephadex G-25), the free
glycan can be converted into the oxazoline by treatment with
DMC in water (Scheme 9), as first reported by Wang [87] and
Umekawa and co-workers [88], and then subsequently used by
others [44,89,90]. Shoda’s modified version of DMC (2-chloro-
1,3-dimethyl-1H-benzimidazol-3-ium chloride, CDMBI) has
also been reported to be efficient at this transformation [91].
Furthermore removal of the terminal sialic acid residues of the
free oligosaccharide by treatment with a neuraminidase allows
the production of truncated complex biantennary glycans. Origi-
nally Wang and co-workers reported [92] the synthesis of this
type of oxazoline using a sequence of acetylation, treatment
with TMSBr/BF3·Et2O/collidine and deacetylation. However,
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 10: Production of a high mannose (Man-9) N-glycan oxazoline from soy bean flour.
treatment of the free reducing sugar with DMC allows the pro-
duction of the truncated complex N-glycan oxazoline in a more
efficient manner [93].
In related work, Kajihara has recently developed [94] methods
that allow selective modification of the complex biantennary
N-glycan available from egg yolks. For example, after the
peptide is degraded to a single Asn residue by protease diges-
tion (Actinase E), the sialic acids can be removed by acidic
hydrolysis [95], and the amine Fmoc protected. Branch specific
exo-glycosidase digestion then allows the production of a wide
variety of truncated glycans. Alternatively, by forming 4,6-
benzylidenes of the mannose and galactose residues, acetylat-
ing all the remaining free OH groups, and then using mild
acidic hydrolysis (60% aqueous acetic acid), Kajihara was able
to produce a mixture of products in which either one or both of
the mannose residues had been deprotected but the galactose
residues remained completely protected. HPLC separation then
allowed either selective chemical glycosylation or protection of
the primary OH groups; the remaining secondary hydroxy
group of the products of the latter process could also be glyco-
sylated. Ultimately this methodology allows the synthesis of the
considerably more complex N-glycans, for example tri- (and
presumably in the future tetra-) antennary glycans, starting from
SGP. Although the protecting group-based reactions lack com-
plete selectivity and the sequences require several careful HPLC
separations, the fact that the complex biantennary glycan is so
readily available still makes these approaches attractive with
respect to total synthesis. Neither Kajihara nor others have yet
to employ these routes to the production of N-glycan oxa-
zolines.
The soy bean approach
Soy bean agglutinin is a glycoprotein decorated with high
mannose glycans [96]. Isolation of soy bean agglutinin from
unroasted soy bean flour is achieved by acidification (pH 4.6),
Beilstein J. Org. Chem. 2018, 14, 416–429.
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Scheme 11: Production of a triantennary N-glycan oxazoline from bovine feruin by semi-synthesis.
and salting out with ammonium sulphate [97,98]. The Asn-
linked Man-9 glycan (Man9GlcNAc2Asn) can then be prepared
[99] by exhaustive Pronase digestion, followed by SEC
(Sephadex G-50) and further purification with HPLC on a
graphitized carbon column (Scheme 10) [100]. Alternatively the
glycan may also be released by hydrazinolysis [101]. Following
isolation of the full-length (Man9GlcNAc2) Asn-linked glycan
the truncated glycan (Man9GlcNAc) can be produced by treat-
ment with the ENGase Endo A [102], and purification by SEC
(Sephadex G-15). The first production of the Man-9 oxazoline
reported by Wang [103] then involved complete acetylation of
this decasaccharide, treatment with TMSBr/BF3·Et2O/collidine,
and a final deacetylation step. However, this method can now
be simplified by use of the Shoda DMC procedure by which the
unprotected Man9GlcNAc glycan can be directly converted to
the oxazoline in water [104]. This route, although lower
yielding than the corresponding egg yolk procedure, is still
considerably more efficient than using total synthesis to make
such a highly complex decasaccharide.
Other routes to N-glycan oxazolines
Recently Wang and co-workers have reported [105] a semi-syn-
thetic route to triantennary N-glycan oxazolines starting from
bovine fetuin (Scheme 11). To enable large-scale production
they first purified bovine fetuin from fetal bovine serum [106].
The N-glycans were then released by treatment with the
ENGase Endo-F3 [107], and were partially purified by acetone
precipitation and extraction with 60% methanol. The crude
N-glycans were found to be a rather complex mixture of com-
pounds, the four major components of which were identified as
triantennary glycans with 2 or 3 sialic acids attached as regio-
isomers (i.e., both α(2–6)- and α(2–3)-linked to the 6-branched
Beilstein J. Org. Chem. 2018, 14, 416–429.
427
mannose arm). Isolation of these major compounds and treat-
ment with a neuraminidase then produced essentially a single
product, which was purified by SEC (Sephadex G-25), and
finally converted to the corresponding triantennary oxazoline by
treatment with DMC in water. Final purification was achieved
by SEC (Sephadex G-15).
Commercially available chicken ovalbumin can be used as a
source of high mannose N-glycans, from which glycopeptides
can be obtained by pronase digestion [108]. A mixture of free
truncated glycans (Man5GlcNAc and Man6GlcNAc) can then
be released [109] by the use of the ENGase Endo A, and sepa-
rated by careful chromatography on a carbon-Celite® column.
Although Wang and co-workers did not at that time report the
conversion of these glycans into the corresponding oxazolines,
the basic Man5GlcNAc structure has since been extended using
a sequence of glycosyl transferases (namely a β(1–2)-GlcNAc
transferase, a β(1–4)-galactosyltransferase, and an α(2–6)-
sialyltransferase), and the corresponding hybrid N-glycan oxa-
zoline used as a substrate for ENGases [110].
Conclusion
N-Glycan oxazolines have found widespread use as activated
donor substrates for ENGase enzymes, a factor which has in
turn stimulated interest in their production both by total synthe-
sis and semi-synthesis. By far the most significant recent break-
through in the field has been the development by Shoda of
DMC (and related reagents), which can effect the direct conver-
sion of oligosaccharides with a 2-acetamido sugar at the
reducing terminus directly into the corresponding glycosyl oxa-
zoline in water. This ‘game-changer’ means that nowadays no
protecting group manipulations are required after oxazoline for-
mation, which is performed as the final step; this makes produc-
tion by total synthesis considerably easier. Additionally the
remarkable ability of DMC and related reagents to achieve this
key transformation also facilitates the use of naturally derived
oligosaccharides as useful sources of N-glycan oxazolines.
Recent work has both simplified the isolation of such N-glycans
from natural sources, such as egg yolks, and also extended the
variety of structures available by such means. It seems likely
that more N-glycans will become available by such methods in
the future. Furthermore it also appears to be only a matter of
time until homogeneous glycoproteins and other glycoconju-
gates produced using N-glycans oxazolines find therapeutic and
other applications; a development which will further stimulate
the search for even better methods for their large scale and cost-
effective production.
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